FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	20549	

STATEMENT	OF	CHANGES	IN BEI	NEFICIAL	. OWNERSH	ΙP

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* TRENARY C RUSSELL III					2. Issuer Name and Ticker or Trading Symbol Outlook Therapeutics, Inc. [OTLK]						ck all applica Director	able)	Perso	on(s) to Issue	ner	
(Last)	(F	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 04/17/2023					<u> </u>	below)	give title		Other (sp below)	pecify	
485 ROU	JTE 1 SOU	TH, BUILDING	F		04/17/2023						CEO and President					
SUITE 3	20			4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						Individual or Joint/Group Filing (Check Applicable Line)					
(Street)											7	Form fil	ed by One	Repor	rting Person	
ISELIN	N	J	08830									Form fil Person	ed by More	than	One Reporti	ng
(City)	(S	tate)	(Zip)	R	Rule	10b5-	1(c)	Transac	ction Ind	ication						
Check this box to indicate that a transaction was made pursuant to a contract, instruct the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.							ct, instruction	on or written plan that is intended to satisfy								
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
Date			:. Transactio Date Month/Day/	Execution Date		e, Transaction Disposed Code (Instr.		ities Acquir d Of (D) (Ins	ed (A) or str. 3, 4 and 5	5. Amoun Securities Beneficia Owned Fo	es Form ally (D) o Following (I) (Ir		Direct II Indirect E str. 4) C	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	Amount	(A) o (D)	r Price	Transaction (Instr. 3 a	action(s)		('		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, Tra ecurity or Exercise (Month/Day/Year) if any Cod		ransa Code (nsaction de (Instr. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year) (Month/Day/Year) 7. Title and of Securiti Underlying Derivative (Instr. 3 and		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)			
Stock Option (Right to Buy)	\$1.08	04/17/2023		A		257,143		(1)	04/17/2033	Common Stock	257,143	\$0.00	257,14	3	D	

Explanation of Responses:

1. 25% of the shares subject to the option shall vest on April 17, 2024, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date. The option is also subject to acceleration under certain circumstances.

Remarks:

/s/ Lawrence Kenyon, Attorney-04/19/2023 in-Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.